| 1 |
34630419 | Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response. | 2021 |
1 |
| 2 |
32539713 | JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells. | 2020 Jun 15 |
2 |
| 3 |
31545408 | Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene. | 2019 Nov |
1 |
| 4 |
27732937 | Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. | 2016 Nov 22 |
1 |
| 5 |
22705984 | Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. | 2012 Jul |
1 |
| 6 |
22960764 | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 Sep 15 |
3 |
| 7 |
21106989 | CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. | 2011 Feb 10 |
1 |
| 8 |
20626385 | The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. | 2010 Aug |
3 |
| 9 |
19855246 | Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. | 2009 Oct 27 |
3 |